Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Astria Contact:

Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Angkor Advances Exploration Independently On Andong Bor License, Cambodia

Angkor Advances Exploration Independently On Andong Bor License, Cambodia

(TheNewswire)

GRANDE PRAIRIE, ALBERTA - August 28, 2025 TheNewswire - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its previous partner, CanBodia Copper Corp. ("CCC") failed to meet its obligations regarding the Andong Bor License.  Following multiple notices to CCC from October 2024 to May 31, 2025, Angkor, through its Cambodian solicitor, filed a Notice of Default with CCC on July 1, 2025, terminating the letter agreement with CCC on the Andong Bor License and declaring the joint relationship null and void.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Bold Ventures Receives Exploration Permits for the Burchell Gold Copper Project and Highlights Ring of Fire News

Bold Ventures Receives Exploration Permits for the Burchell Gold Copper Project and Highlights Ring of Fire News

Bold Ventures Inc. (TSXV: BOL,OTC:BVLDF) (the "Company" or "Bold") is pleased to announce that it has received two exploration permits for work at the Burchell Gold Copper Project. The applications were made as a result of recent exploration work in and around the "111 Zone" gold discovery (see Bold News Release dated January 9, 2025) and the strike extension of the Moss Trend on the adjacent Moss Gold Property of Goldshore Resources Inc. to the west (see Bold New Release dated July 21, 2025 and Bold News Release dated August 18, 2025). The Burchell Property is located approximately 100 km west of Thunder Bay, Ontario.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Heritage Mining Provides Exploration and Melba Project Update

Heritage Mining Provides Exploration and Melba Project Update

(TheNewswire)

NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Group Eleven Drills 6.2m of 312 g/t Ag and 0.95% Cu, incl. 2.8m of 549 g/t Ag and 1.77% Cu in a 90m Step-Out, Further Supporting Deeper Cu-Ag Target at Ballywire

Group Eleven Drills 6.2m of 312 g/t Ag and 0.95% Cu, incl. 2.8m of 549 g/t Ag and 1.77% Cu in a 90m Step-Out, Further Supporting Deeper Cu-Ag Target at Ballywire

Group Eleven Resources Corp. (TSXV: ZNG,OTC:GRLVF) (OTCQB: GRLVF) (FSE: 3GE) ("Group Eleven" or the "Company") is pleased to announce the latest three step-out drill holes from the discovery horizon at its Ballywire discovery ("Ballywire") at the 100%-owned PG West Project ("PG West"), Republic of Ireland. Drilling at Ballywire's deeper, Cu-Ag target (100-200m below discovery horizon) is in progress (to be reported as soon as possible).

Highlights:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Prismo Metals Discovers Two Separate Mineralized Veins at Silver King

Prismo Metals Discovers Two Separate Mineralized Veins at Silver King

(TheNewswire)

Prismo to Host Webinar on September 3rd

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×